Enhanced antileukemic effect of NKp30b isoform of donor-derived NK cells infused after HLA-haploidentical allogeneic hematopoietic cell transplantation in high-risk AML and MDS.

COI Statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Ethics approval was granted by the Institutional Review Board of Asan Medical Center (2014-1091, 2018-0349). Informed consent was obtained from all participants, and all methods adhered to relevant guidelines and regulations.

References:

• DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136:1023–32. https://doi.org/10.1182/blood.2019001982
• Lee KH, Yoon SR, Gong JR, Choi EJ, Kim HS, Park CJ, et al. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial. Leukemia. 2023;37:807–19. https://doi.org/10.1038/s41375-023-01849-5 .
• Yoon S, Lee Y, Yang S, Ahn K, Lee J-H, Lee J-H, et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45:1038–46.
• Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Jang YJ, et al. Donor-derived natural killer cells infused after human leukocyte antigen–haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20:696–704.
• Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Kang Y-L, et al. Donor-derived natural killer cell infusion after human leukocyte antigen–haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2016;22:2065–76.